A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma

Acta Oncologica

Volumn 40, Issue 2-3, 2001, Pages 213-223

  Brandt, L ^a   Kimby, E ^b   Nygren, P ^c   Glimelius, B ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE; BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; EPIRUBICIN; INTERFERON; MITOXANTRONE; PREDNIMUSTINE; PREDNISOLONE; PROCARBAZINE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE; VINCRISTINE SULFATE;

BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; DRUG RESPONSE; FOLLICULAR LYMPHOMA; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME; WELLBEING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; PALLIATIVE CARE; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0034960334     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860151116286     Document Type: Review

References (110)

1. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
2. What's the deal with follicular lymphomas?
3. Malignant lymphoma: A clinicopathologic survey of 618 cases
4. Follicular lymphoma: Prognostic factors for response and survival
5. Low-grade lymphoma 1993: State of the art
6. The follicular non-Hodgkin's lymphomas - II. Prognostic factors: What do they mean?
7. Is the international prognostic index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients
8. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma
9. The role of radiation therapy in the management of the non-Hodgkin's lymphoma
10. Lymphocytic lymphomas
11. Is radiotherapy curative for stage I and 11 low grade follicular lymphoma? Results of long-term follow-up study of patients treated at Stanford University
12. Management of the low-grade non-Hodgkin's lymphomas
13. The follicular non-Hodgkin's lymphomas. - I. The possibility of cure
14. Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute
15. Analysis of non-Hodgkin's lymphomas with nodular and favorable histologies, stages I and II
16. Combined radiotherapy-chemotherapy for early stages non-Hodgkin's lymphoma: The 1975-1980 EORTC controlled lymphoma trial
17. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkin's lymphoma
18. CVP-remission-maintenance in stage I-II non-Hodgkin's lymphomas
19. Improved five-year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma
20. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas
21. Adjuvant cyclophosphamide, doxorubicine, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma
22. Radiotherapy in the treatment of localised non-Hodgkin's lymphoma (Report no 16)
23. Long-term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma
24. Stage I-II low-grade lymphomas: A prospective trial of combination chemotherapy and radiotherapy
25. High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma
26. Watch and wait policy for patients with non Hodgkin's lymphoma clinical stage I or IE with no lymphoma left following diagnostic surgery
27. Wait and see policy in stage I follicular lymphoma
28. No initial therapy for stage III and IV lymphomas of favorable histologic types
29. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alpha: A randomized study from the Groupe D'Etudes des Lymphomes Folliculaires
30. The natural history of initially untreated low-grade non-Hodgkin's lymphomas
31. Primarily asymptomatic low-grade non-Hodgkin lymphomas: Prediction of symptom-free survival and total survival
32. The treatment of indolent lymphomas: Watchful waiting versus aggressive combined modality treatment
33. Prednimustine v cyclophosphamide-vincristine-prednisolone in the treatment of non-Hodgkin's lymphoma with favorable histopathology: Results of a National Cancer Care Program in Sweden
34. The treatment of advanced stage favorable histology non-Hodgkin's lymphomas: A preliminary report of a randomized trial comparing single-agent chemotherapy, combination chemotherapy, and whole body irradiation
35. Non-Hodgkin's lymphomas. II Single agent chemotherapy
36. Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histologic type
37. Clinical evaluation of CB 1348 in malignant lymphoma and related diseases
38. Combination versus successive single agent chemotherapy in lymphocytic lymphoma
39. Interferon Alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival
40. Chemotherapy of non-Hodgkin's lymphomas
41. Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias
42. 2-Chlorodeoxyadenosine activity with untreated, indolent non-Hodgkin's malignant lymphoma
43. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte
44. Purine nucleoside analogs: Emerging roles in indolent lymphoproliferative disorders
45. SWOG 95-01: A phase II trial of a combination of fludarabine and mitoxantrone in untreated advanced low-grade lymphoma: An effective well-tolerated therapy
46. Preliminary results from a prospective randomised phase III trial of fludarabine vs CVP chemotherapy in newly diagnosed patients with stage III & IV low grade NHL
47. Moderate vs aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma
48. Nodular mixed lymphoma: Results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy
49. Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: Preliminary results of a prospective trial
50. Combination chemotherapy in non-Hodgkin's lymphoma: Results of long-term follow-up
51. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: A randomized trial from the Lymphoma Group of Central Sweden
52. Combination chemotherapy of the malignant lymphomas
53. Combination chemotherapy ("CHOP-Bleo") in advanced non-Hodgkin's malignant lymphoma
54. Long-term follow up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy
55. Low-dose total body irradiation versus combination chemotherapy for lymphomas with follicular growth pattern
56. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma
57. Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma
58. Recombinant interferon alpha-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma
59. Doxorubicin-containing regimen with or without interferon alpha-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial
60. Interferon alpha plus chemotherapy for non-Hodgkin's lymphoma: Five-year follow-up
61. Interferon in non-Hodgkin's lymphoma an update of the ECOG I-COPA trial (E6484)
62. Role of interferon alpha-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: Results from a prospective, multicenter trial with double randomization
63. Randomized study of chlorambucil (CB) compared to interferon (alpha-2b) combined with CB in low-grade non-Hodgkin's lymphoma: An interim report of randomized study
64. Cyclophosphamide versus cyclophosphamide plus interferon alpha-2b in follicular low-grade lymphomas: A preliminary report of an intergroup trial (CALGB 8691 and EST 7489)
65. Cyclophosphamide versus cyclophosphamide plus interferon alpha-2b in follicular low-grade lymphomas: An intergroup phase III trial (CALGB 8691 and EST 7486)
66. Interferon-alpha 2b in the treatment of follicular lymphoma: Preliminary results of a trial in progress
67. The role of interferon in follicular lymphoma
68. Quality-of-life-adjusted analysis of Interferon Alpha-2b treatment for advanced follicular lymphoma: An aid to clinical decision making
69. Interferon alpha for the treatment of follicular lymphomas
70. Fludarabine in low-grade lymphoma
71. Fludarabine single agent therapy for relapsed low-grade lymphomas: A phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group
72. Activity of fludarabine in previously treated non-Hodgkin's lymphoma: Results of an Eastern Cooperative Oncology Group study
73. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma
74. Fludarabine phosphate for the treatment of low grade lymphoid malignancy
75. Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma
76. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma
77. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas
78. Phase III trial comparing fludarabine to CVP in patients with recurrent low grade non-Hodgkin's lymphomas (Ig-HL)
79. Fludarabine, mitoxantrone and dexamethasone: An effective new regimen for indolent lymphoma
80. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma
81. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon
82. Interferon alpha in lymphoma
83. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
84. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of the patients respond to a four-dose treatment program
85. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
86. 131I]anti-B1 (anti-CD20) antibody
87. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
88. IDEC-C2B8/CHOP chemoimmunotherapy in patients with low-grade lymphoma: Interim clinical and bcl-2 (PCR) results
89. Phase II pilot study of the safety and efficacy of Rutimax in combination with CHOP chemotherapy in patients with previously untreated intermediate- Or high-grade NHL
90. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment related mortality in 100 patients in sensitive relapse
91. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor prognosis follicular lymphoma
92. High dose therapy with autologus hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
93. Value of autologous bone marrow transplantation in follicular lymphoma: A France Autograffe retrospective study of 42 patients
94. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: A study of 27 patients from a single centre
95. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission
96. Preparation and successful engraftment of purified CD34+ bone marrow progenitor cells in patients with non-Hodgkin's lymphoma
97. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
98. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma
99. Autologus bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high risk follicular lymphoma: A pilot study of 34 cases
100. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma
101. Autologous bone marrow transplantation for low-grade non-Hodgkin's lymphoma: The European Bone Marrow Transplant Group experience
102. Outcome of high dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest
103. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma
104. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: A case-matched comparison with unpurged cases by the European Blood and Marrow Transplant lymphoma registry
105. The CUP trial: A randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodkgin's lymphoma (NHL)
106. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management
107. Prospective comparative trial of autologus versus allogenic bone marrow transplantation in patients with non-Hodgkin's lymphoma
108. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma
109. Allogeneic bone marrow transplantation for low-grade lymphoma